Mitochondrial myopathy caused by arsenic trioxide therapy

Blood

Volumn 119, Issue 18, 2012, Pages 4272-4274

  Echaniz Laguna, Andoni ^a,b   Benoilid, Aurélien ^a   Vinzio, Stéphane ^c   Fornecker, Luc Matthieu ^c   Lannes, Béatrice ^c   Goullé, Jean Pierre ^d   Broly, Frank ^e   De Camaret, Bénédicte Mousson ^f  

^a HÔPITAL DE HAUTEPIERRE   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^d LE HAVRE HOSPITAL   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f Centre Hospitalier Universitaire Lyon   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; FAT DROPLET; MITOCHONDRIAL DNA;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; DRUG WITHDRAWAL; FEMALE; GENE DELETION; HUMAN; MITOCHONDRIAL MYOPATHY; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYALGIA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RESPIRATORY CHAIN; TREATMENT DURATION;

EID: 84860830597     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-10-385138     Document Type: Article

References (24)

1. Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006; 107(7):2627-2632.
2. Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107(9):3469-3473.
3. Sanz MA, Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol. 2011;29(5):495-503.
4. Chen SJ, Zhou GB, Zhang XW, Mao JH, de ThéH, Chen Z. From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood. 2011;117(24):6425-6437.
5. Argos M, Kalra T, Rathouz PJ, et al. Arsenic exposure from drinking water, and all-cause and chronic-disease mortalities in Bangladesh (HEALS): a prospective cohort study. Lancet. 2010;376(9737):252-258.
6. Klaassen CD. Major toxic metals: arsenic. In: Klaassen CD, ed. Casarett and Doull's Toxicology: The Basic Science of Poisons (Revised 7th Ed.). New York, NY: McGraw-Hill Medical; 2008:936-939.
7. Partridge MA, Huang SXL, Hernandez-Rosa E, Davidson MM, Hei TK. Arsenic induced mitochondrial damage and altered mitochondrial oxidative function: implications for genotoxic mechanisms in mammalian cells. Cancer Res. 2007;67(11):5239-5247. (Pubitemid 46997262)
8. Liu SX, Davidson MM, Tang X, et al. Mitochondrial damage mediates genotoxicity of arsenic in mammalian cells. Cancer Res. 2005;65(8):3236-3242. (Pubitemid 40524606)
9. Miranda N, Oliveira P, Frade MJ, Melo J, Marques MS, Parreira A. Myositis with tretinoin. Lancet. 1994;344(8929):1096.
10. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukaemia: recommendations from an expert panel on behalf of the European LeukaemiaNet. Blood. 2009;113(9):1875-1891.
11. Fanton L, Duperret S, Guillaumée F, Miras A, Vallon JJ, Malicier D. Fatal rhabdomyolysis in arsenic trioxide poisoning. Hum Exp Toxicol. 1999;18(10):640-641. (Pubitemid 29531306)
12. Sanz P, Corbella J, Noque S, Munne P, Rodriguez-Pazos M. Rhabdomyolysis in fatal arsenic trioxide poisoning. JAMA. 1989;262(23):3271. (Pubitemid 20012542)
13. Fernandez-Sola J, Nogue S, Grau JM, Casademont J, Munne P. Acute arsenical myopathy: morphological description. J Toxicol Clin Toxicol. 1991;29(1):131-136.
14. Higuchi I, Izumo S, Kuriyama M, et al. Germanium myopathy: clinical and experimental pathological studies. Acta Neuropathol. 1989;79(3):300-304. (Pubitemid 20017603)
15. Steinmaus C, Moore LE, Shipp M, et al. Genetic polymorphisms in MTHFR 677 and 1298, GSTM1 and T1, and metabolism of arsenic. J Toxicol Environ Health A. 2007;70(2):159-170.
16. Belzacq AS, El Hamel C, La Vieira H, et al. Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437. Oncogene. 2001;20(52):7579-7587. (Pubitemid 33111858)
17. Das J, Ghosh J, Manna P, Sil PC. Protective role of taurine against arsenic-induced mitochondriadependent hepatic apoptosis via the inhibition of PKCdelta-JNK pathway. PLoS One. 2010;5(9):e12602.
18. Santra A, Chowdhury A, Ghatak S, Biswas A, Krishna Dhali G. Arsenic induced apoptosis in mouse liver is mitochondria dependent and is abrogated by N-acetylcysteine. Toxicol Appl Pharmacol. 2007;220(2):146-155. (Pubitemid 46507569)
19. Du L, Yu Y, Chen J, et al. Arsenic induces caspase and mitochondria mediated apoptosis in Saccharomyces cerevisiae. FEMS Yeast Res. 2007;7(6):860-865. (Pubitemid 47256376)
20. Yen YP, Tsai KS, Chen YW, Huang CF, Yang RS, Liu SH. Arsenic inhibits myogenic differentiation and muscle regeneration. Environ Health Perspect. 2010;118(7):949-956.
21. Carter DE, Aposhian HV, Gandolfi AJ. The metabolism of inorganic arsenic oxides, gallium arsenide, and arsine: a toxicochemical review. Toxicol Appl Pharmacol. 2003;193(3):309-334. (Pubitemid 37543540)
22. Shoubridge EA, Johns T, Karpati G. Complete restoration of a wild-type mtDNA genotype in regenerating muscle fibres in a patient with a tRNA point mutation and mitochondrial encephalomyopathy. Hum Mol Genet. 1997;6(13):2239-2242. (Pubitemid 27501074)
23. Clark KM, Bindoff LA, Lightowlers RN, et al. Reversal of a mitochondrial DNA defect in human skeletal muscle. Nat Genet. 1997;16(3):222-224.
24. Krishnan KJ, Greaves LC, Reeve AK, Turnbull DM. Mitochondrial DNAmutations and aging. Ann N Y Acad Sci. 2007;1100:227-240.